Novocure’s Flex Assay Brain Tumor Treatment Receives CE Mark

Novocure has gained the CE mark for its new flex array for delivery of tumor treating fields (TTFields) to patients with glioblastoma.

The TTFields system uses small transducers attached to the scalp with adhesive bandages. The transducers are connected to a battery about the size of a book. Patients carry the device with them — in a backpack or bag — for continuous treatment of brain tumors using electric fields that kill cancer cells.

The new array is more than 50 percent thinner and more than 30 percent lighter than current commercial arrays, the company said.

Novocure is initially planning a limited market release in Europe. “Initial patient experience will inform regulatory filings and launch plans in additional active markets,” the company says.